WFRF:(Johnson David C.)
Sökning: WFRF:(Johnson David C.) > The societal value ...
- 456 av 495
- Föregående post
- Nästa post
- Till träfflistan
The societal value of SARS-CoV-2 booster vaccination in Indonesia
-
- Johnson, Rob (författare)
- MRC Centre for Global Infectious Disease Analysis & WHO Collaborating Centre for Infectious Disease Modelling, Jameel Institute for Disease and Emergency Analytics, Imperial College London, United Kingdom
-
- Djaafara, Bimandra (författare)
- MRC Centre for Global Infectious Disease Analysis & WHO Collaborating Centre for Infectious Disease Modelling, Jameel Institute for Disease and Emergency Analytics, Imperial College London, United Kingdom; Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia
-
- Haw, David (författare)
- MRC Centre for Global Infectious Disease Analysis & WHO Collaborating Centre for Infectious Disease Modelling, Jameel Institute for Disease and Emergency Analytics, Imperial College London, United Kingdom
- visa fler...
- visa färre...
- (creator_code:org_t)
- Elsevier, 2023
- 2023
- Engelska.
- Ingår i: Vaccine. - : Elsevier. - 0264-410X .- 1873-2518. ; 41:11, s. 1885-1891
- Tidskriftsartikel (refereegranskat)
Abstract
Ämnesord
Stäng
- Objectives: To estimate the expected socio-economic value of booster vaccination in terms of averted deaths and averted closures of businesses and schools using simulation modelling.Methods: The value of booster vaccination in Indonesia is estimated by comparing simulated societal costs under a twelve-month, 187-million–dose Moderna booster vaccination campaign to costs without boosters. The costs of an epidemic and its mitigation consist of lost lives, economic closures and lost education; cost-minimising non-pharmaceutical mitigation is chosen for each scenario.Results: The cost-minimising non-pharmaceutical mitigation depends on the availability of vaccines: the differences between the two scenarios are 14 to 19 million years of in-person education and $153 to $204 billion in economic activity. The value of the booster campaign ranges from $2,500 ($1,400-$4,100) to $2,800 ($1,700-$4,600) per dose in the first year, depending on life-year valuations.Conclusions: The societal benefits of booster vaccination are substantial. Much of the value of vaccination resides in the reduced need for costly non-pharmaceutical mitigation. We propose cost minimisation as a tool for policy decision-making and valuation of vaccination, taking into account all socio-economic costs, and not averted deaths alone.
Ämnesord
- SAMHÄLLSVETENSKAP -- Ekonomi och näringsliv -- Nationalekonomi (hsv//swe)
- SOCIAL SCIENCES -- Economics and Business -- Economics (hsv//eng)
Nyckelord
- COVID-19
- Economics
- Education
- Non-pharmaceutical
- Vaccination
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
- 456 av 495
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Johnson, Rob
- Djaafara, Bimand ...
- Haw, David
- Doohan, Patrick
- Forchini, Giovan ...
- Pianella, Matteo
- visa fler...
- Ferguson, Neil
- Smith, Peter C.
- Hauck, Katharina ...
- visa färre...
- Om ämnet
-
- SAMHÄLLSVETENSKAP
- SAMHÄLLSVETENSKA ...
- och Ekonomi och näri ...
- och Nationalekonomi
- Artiklar i publikationen
- Vaccine
- Av lärosätet
- Umeå universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
